HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.

Abstract
The efficacy of intravenous peramivir against influenza A (H1N1) 2009 virus infection was evaluated in mice in which the immune system was suppressed by cyclophosphamide (CP) treatment. The mortality rate of the vehicle control group was 100%, and the mice lost 20% of their body weight on average by day 13 postinfection (p.i.). Repeated administration of peramivir (40 mg/kg of body weight once a day, given intravenously for 20 days), starting at 1 h p.i., significantly reduced mortality, body weight loss, viral titers, and cytokine production in infected mice compared with results for administration of vehicle (P < 0.01). In addition, repeated administration of peramivir, starting at 24 h, 48 h, or 72 h p.i., also resulted in increases in survival rates and reduction of viral titers in the lungs (P < 0.01). The mean days to death (MDD) of the vehicle group was 14.5 days, while in the groups treated with peramivir starting at 24 h, 48 h, and 72 h p.i., the MDDs were >23.0, 20.9, and 21.8 days, respectively. In comparison, repeated administration of oseltamivir phosphate (5 mg/kg twice a day, given orally for 20 days), starting at 24 h, 48 h, and 72 h p.i., also significantly prevented body weight loss, whereas no significant differences in mortality rates and viral titers in the lungs were observed compared with results for the vehicle group. These data indicated that repeated administration of peramivir was effective in promoting the survival and reducing virus replication in immunosuppressed mice infected with influenza A (H1N1) 2009 virus.
AuthorsMitsutaka Kitano, Makoto Kodama, Yasushi Itoh, Takushi Kanazu, Masanori Kobayashi, Ryu Yoshida, Akihiko Sato
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 57 Issue 5 Pg. 2286-94 (May 2013) ISSN: 1098-6596 [Electronic] United States
PMID23478960 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Acids, Carbocyclic
  • Antiviral Agents
  • Cyclopentanes
  • Guanidines
  • Immunosuppressive Agents
  • Phosphorous Acids
  • tamiphosphor
  • Oseltamivir
  • Cyclophosphamide
  • peramivir
Topics
  • Acids, Carbocyclic
  • Animals
  • Antiviral Agents (pharmacology)
  • Body Weight (drug effects)
  • Cyclopentanes (pharmacology)
  • Cyclophosphamide (pharmacology)
  • Drug Administration Schedule
  • Female
  • Guanidines (pharmacology)
  • Immunosuppressive Agents (pharmacology)
  • Influenza A Virus, H1N1 Subtype (drug effects, growth & development)
  • Injections, Intravenous
  • Lung (drug effects, immunology, virology)
  • Mice
  • Mice, Inbred BALB C
  • Orthomyxoviridae Infections (drug therapy, immunology, mortality, virology)
  • Oseltamivir (analogs & derivatives, pharmacology)
  • Phosphorous Acids (pharmacology)
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: